Health Care
9.2% — Share of covered S&P 500 companies' positive net income (10-K/20-F) · 60 companies, sorted by earnings share. Our calculation from filings, not an index weight. “deep dive →” marks a full earnings card.
Companies: earnings share and revenue growth
Sector revenue growth y/y (weighted by earnings share): +11%
Color scale
How to read the map
Rectangle size is the company’s share of S&P 500 companies’ shareholder earnings; together they make up the whole sector. On a wide screen companies are grouped by GICS industry, labelled above each group. The tiniest ones are combined into a “+N” tile.
Color is revenue growth y/y in the latest report: red — revenue fell, green — it grew (darker is stronger), light — roughly flat (±1%), hatched — no data.
Share of covered S&P 500 companies' positive net income (10-K/20-F). Our calculation from company filings, not an index weight. Each company's latest full fiscal year (periods may differ), profit attributable to owners of the parent in USD: consolidated profit excluding noncontrolling interests. This is not a dividend measure. Losses and zero earnings receive a zero share. Coverage: 473 of 499 issuers; 26 without unambiguously extractable data are excluded from the denominator. The denominator sums positive earnings of covered issuers; each company is counted once regardless of its number of share classes. Checked 2026-11-16; refresh after annual filings and membership changes, check at least monthly. Membership: S&P DJI releases; GICS sectors: constituent register. Color: year-over-year revenue change in the latest quarter, from SEC XBRL and our report cards. Tap a tile to open the report; if the ticker didn’t fit on the tile or there is no report yet, we show the name and numbers.
The latest reports of 60 companies in the sector at a glance. Fastest revenue growth: Waters (+121%); slowest: Charles River Laboratories International (−2.2%). Largest net income: Eli Lilly and Company. Full comparison below.
Latest earnings: Health Care compared
| Johnson & Johnson | Q3 2026 | $25,399+5.9% | $210−95.9% | Oct 13, 2026 |
| Eli Lilly and Company | Q3 2026 | $24,397+38.6% | $6,451+15.5% | Oct 29, 2026 |
| Merck & Co. | Q3 2026 | $18,085+4.7% | $5,065−12.4% | Oct 29, 2026 |
| UnitedHealth Group | Q3 2026 | $112,694−0.4% | $4,110+75.0% | Oct 13, 2026 |
| Gilead Sciences | Q3 2026 | $8,300+6.8% | $2,429−20.4% | Oct 29, 2026 |
| Pfizer | Q3 2026 | $16,583−0.4% | $3,242−8.4% | Nov 3, 2026 |
| Amgen | Q3 2026 | $10,365+8.5% | $3,864+20.1% | Nov 3, 2026 |
| Bristol Myers Squibb | Q3 2026 | $13,069+6.9% | $2,162−1.8% | Oct 29, 2026 |
| HCA Healthcare | Q3 2026 | $19,849+3.6% | $1,579−3.9% | Oct 27, 2026 |
| Thermo Fisher Scientific | Q3 2026 | $12,137+9.1% | $1,721+6.5% | Oct 21, 2026 |
| Abbott Laboratories | Q3 2026 | $13,013+14.5% | $920−44.0% | Oct 21, 2026 |
| Cigna | Q3 2026 | $73,683+5.6% | $1,442−22.8% | Nov 5, 2026 |
| Elevance Health | Q3 2026 | $51,429+1.4% | $1,365+14.8% | Oct 21, 2026 |
| Medtronic | Q1 2027 previous | $9,756+13.7% | $1,470+41.4% | Sep 1, 2026 |
| McKesson | Q1 FY2027 previous | $105,380+7.7% | $1,032+24.2% | Aug 5, 2026 |
| Regeneron Pharmaceuticals | Q3 2026 | $5,116+36.3% | $1,949+33.5% | Oct 30, 2026 |
| AbbVie | Q3 2026 | $17,404+10.3% | $4,218 | Oct 30, 2026 |
| Vertex Pharmaceuticals | Q3 2026 | $3,441+11.8% | $654−39.6% | Nov 2, 2026 |
| Danaher | Q3 2026 | $6,554+8.3% | $1,235+36.0% | Oct 21, 2026 |
| Stryker | Q3 2026 | $6,520+7.6% | $753−12.3% | Oct 29, 2026 |
| Boston Scientific | Q3 2026 | $5,138+1.4% | $582−22.9% | Oct 28, 2026 |
| Intuitive Surgical | Q3 2026 | $3,049+21.7% | $523−25.8% | Oct 20, 2026 |
| Zoetis | Q3 2026 | $2,391−1.3% | $591−18.0% | Nov 5, 2026 |
| GE HealthCare Technologies | Q3 2026 | $5,513+7.2% | $615+37.9% | Oct 28, 2026 |
| CVS Health | Q3 2026 | $108,399+5.4% | $2,172 | Nov 4, 2026 |
| Cardinal Health | Q1 FY2027 | $67,513+5.5% | $554+23.1% | Nov 5, 2026 |
| Becton, Dickinson | Q4 FY2026 previous | $5,274+5.4% | $696+41.2% | Nov 5, 2026 |
| Solventum | Q2 2026 previous | $2,209+2.2% | $92+2.2% | Aug 5, 2026 |
| Cencora | Q4 FY2026 previous | $88,355+5.5% | $519 | Nov 4, 2026 |
| ResMed | Q1 FY2027 | $1,415+5.9% | $418+20.0% | Oct 29, 2026 |
| Universal Health Services | Q3 2026 | $4,733+5.3% | $309−17.2% | Oct 27, 2026 |
| IQVIA | Q3 2026 | $4,428+8.0% | $350+5.7% | Oct 27, 2026 |
| Agilent Technologies | Q3 FY2026 previous | $1,878+8.1% | $362+7.7% | Aug 26, 2026 |
| Biogen | Q3 2026 | $2,804+10.6% | — | Oct 28, 2026 |
| Incyte | Q2 2026 previous | $1,674+37.7% | $586+44.6% | Jul 28, 2026 |
| Humana | Q2 2026 previous | $40,867+26.2% | $694+27.3% | Jul 29, 2026 |
| Edwards Lifesciences | Q2 2026 previous | $1,741+13.6% | $242−27.4% | Jul 23, 2026 |
| IDEXX Laboratories | Q3 2026 | $1,214+9.9% | $317+15.5% | Nov 2, 2026 |
| Quest Diagnostics | Q3 2026 | $3,097+10.0% | $312+27.3% | Oct 22, 2026 |
| Veeva Systems | Q2 FY2027 previous | $928+17.6% | $273+36.5% | Aug 26, 2026 |
| Labcorp | Q3 2026 | $3,810+6.9% | $263+0.7% | Oct 28, 2026 |
| Mettler-Toledo International | Q3 2026 | $1,094+6.3% | $246+13.1% | Nov 5, 2026 |
| Illumina | Q3 2026 | $1,129+4.2% | $220+46.7% | Oct 29, 2026 |
| DexCom | Q3 2026 | $1,345+11.2% | $275−3.1% | Oct 29, 2026 |
| STERIS | Q2 FY2027 previous | $1,589+8.8% | $214+11.4% | Nov 4, 2026 |
| DaVita | Q3 2026 | $3,578+4.6% | $223+48.3% | Oct 29, 2026 |
| Zimmer Biomet | Q3 2026 | $2,063+3.1% | $192−17.0% | Nov 4, 2026 |
| Waters | Q3 2026 | $1,767+121% | $81−45.6% | Nov 3, 2026 |
| West Pharmaceutical Services | Q3 2026 | $875+8.7% | $214+52.9% | Oct 29, 2026 |
| Align Technology | Q3 2026 | $1,015+1.9% | $135+138% | Oct 28, 2026 |
| Henry Schein | Q3 2026 | $3,471+4.0% | $119+17.8% | Nov 3, 2026 |
| Cooper | Q3 FY2026 previous | $1,066+0.6% | $433+340% | Sep 9, 2026 |
| Insulet | Q3 2026 | $842+19.2% | $141+61.1% | Nov 4, 2026 |
| Revvity | Q3 2026 | $729+4.3% | $62.3+33.5% | Nov 3, 2026 |
| Baxter International | Q3 2026 | $2,976+5.0% | $294 | Oct 29, 2026 |
| Centene | Q3 2026 | $50,647+1.9% | — | Oct 27, 2026 |
| Charles River Laboratories International | Q3 2026 | $983−2.2% | $333+512% | Nov 4, 2026 |
| Moderna | Q2 2026 previous | $145+2.1% | — | Jul 31, 2026 |
| Bio-Techne | Q4 FY2026 previous | $321+1.3% | $54.6 | Aug 12, 2026 |
| Viatris | Q2 2026 previous | $3,757+4.9% | — | Aug 6, 2026 |
Amounts in $ millions; changes vs the same period a year earlier. Figures come from our verified earnings breakdowns; fiscal periods differ between companies.
Shareholders’ equity in Health Care
Negative equity: HCA Healthcare (−$8.1B), AbbVie (−$4.6B), McKesson (−$4.0B), Cardinal Health (−$3.0B), DaVita (−$0.59B). Equity, assets and change since year-end →
Other sectors
Information Technology 28.9% · Financials 20.6% · Communication Services 13% · Industrials 7.9% · Consumer Discretionary 7.6% · Consumer Staples 4.7% · Energy 2.8% · Utilities 2.4% · Materials 1.6% · Real Estate 1.3%